Silicosis treatment

Alternative Silicosis Treatment Available at the Lung Institute

Traditional treatment for silicosis includes inhaled steroids and oxygen support, but these treatments typically only focus on the management of symptoms. While these options work for some people, others may experience negative side effects, such as an adverse reaction to a medication or a limitation on movement due to an oxygen machine. As an alternative treatment for silicosis, the Lung Institute offers stem cell therapy. This groundbreaking therapy centers around the fact that adult stem cells are undifferentiated, which means they have the ability to self-renew and replicate to form and function as any other type of tissue in the body. We use autologous stem cells in our procedures, which means the stem cells are derived from the patient’s own body. As a result, this alternative silicosis treatment is safe and comes with no risk of rejection.

The Lung Institute offers two different forms of stem cell therapy for the treatment of silicosis, both with the goal of reducing lung inflammation, improving lung function and slowing disease progression. These forms include:

  • Venous (blood-derived) stem cell therapy
  • Bone marrow stem cell therapy

Both of these procedures are minimally invasive and are performed on an outpatient basis over the course of two days. Patients will be guided through every step of the treatment by our friendly and caring medical staff. Most patients are able to immediately return to daily activities after their procedure, and many report an improvement in their overall quality of life as a result of stem cell therapy.

To learn more about the stem cell therapy we offer as an alternative treatment for silicosis, as well as options for prevention, call the Lung Institute today at (800) 729-3065.

* All treatments performed at Lung Institute utilize autologous stem cells, meaning those derived from a patient's own body. No fetal or embryonic stem cells are utilized in Lung Institute's procedures. Lung Institute aims to improve patients' quality of life and help them breathe easier through the use of autologous stem cell therapy. To learn more about how stem cells work for lung disease, click here.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

Under current FDA guidelines and regulations 1271.10 and 1271.15, the Lung Institute complies with all necessary requirements for operation. The Lung Institute is firmly in accordance with the conditions set by the FDA for exemption status and conducts itself in full accordance with current guidelines. Any individual who accesses Lung Institute's website for information is encouraged to speak with his or her primary physician for treatment suggestions and conclusive evidence. All information on this site should be used for educational and informational use only.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and stem cell procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.